HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
